The Weight Loss Hormone GDF15 Protects the Liver, Even Without Weight Loss, Mouse Study Finds
GDF15 has mostly been in the news as the hormone that helps explain why some obesity drug candidates suppress appetite. A new study out of McMaster University suggests it does something else entirely, and the twist is that it does not need weight loss to do it.
- GDF15, the appetite suppressing hormone behind a wave of next generation obesity drug candidates, has been shown by McMaster University researchers to activate a previously unknown brain to liver signaling pathway.
- That pathway releases glucocorticoids, steroid hormones central to metabolism and immune function, which calm liver inflammation and slow the scarring seen in advanced fatty liver disease in mouse models.
- The protection happened independently of food intake, body weight or liver fat, meaning it is decoupled from GDF15's better known appetite and weight effects.
- This is mouse work, and Novo Nordisk collaborated on and helped fund the study. There is no human GDF15 therapy available today, so there is nothing here a reader can act on beyond understanding the mechanism.
A separate switch for the liver
Findings like this one start in mouse models, years before any human study is possible.
Andrey ChernogorodovCC BY 4.0
Illustrative: a different university's lab, not the McMaster research described here.
Working primarily in mouse models of MASH, the advanced form of fatty liver disease that causes inflammation and scarring, the McMaster team found that GDF15 activates a brain to liver signaling route. GDF15 triggers signaling from the brain through the nervous system that causes the release of glucocorticoids, steroid hormones central to metabolism, immune function and the body's stress response. Those glucocorticoids then dampen inflammation in the liver and limit the progression of fibrosis, the scarring that marks advanced liver disease. Using spatial transcriptomics, the researchers also showed GDF15 reprogramming liver immune cells into a more protective, less activated state.
The part that makes this more than a footnote to GDF15's appetite story is that the liver benefit showed up with no accompanying change in how much the mice ate, what they weighed, or how much fat their livers held. In other words, the mechanism protecting the liver here is not just weight loss working its way downstream. It appears to be a separate, direct pathway.
Food intake
No difference in how much the mice ate.
Body weight
No difference in body weight between groups.
Liver fat
No difference in how much fat the liver held.
The liver protection this brain to liver pathway produced in mouse models of advanced fatty liver disease showed up without moving any of the three numbers most people would assume have to change first.
Why weight loss and liver inflammation may be two different problems
This matters for a very practical reason. Liver inflammation stubbornly persists in many real patients even after major weight loss on current GLP-1 medications. If GDF15's liver protecting effect really is independent of weight and food intake, that reframes what "the liver got better" might require going forward. Researchers are increasingly saying openly that the next generation of treatment may need to target the liver and the metabolic side as two separate problems, rather than assuming fixing one automatically fixes the other.
Honest caveat
This is mouse work. MASH models mimic human liver disease but do not replicate it exactly, and a brain to liver pathway shown in mice may work differently, or not at all, in people. There is also a real interest structure worth naming plainly: Novo Nordisk collaborated on the study, provided research support and supplied the GDF15 used in it, and the senior author is chief scientific officer, a shareholder and co founder of a company developing a drug candidate for advanced liver disease. That does not make the finding false, but it means the result is unproven until an unconflicted group replicates it. Non commercial funders, including Canadian government science agencies, partly offset this. There is no human GDF15 therapy available today, so there is nothing here to act on beyond understanding the mechanism, and it is worth remembering that high circulating GDF15 in humans is actually a known marker of illness and wasting, so more GDF15 is not automatically a good thing.
weight and liver inflammation look like two separate dials, and future treatment may need to turn both
What this means for you
If you are on or considering a GLP-1 medication and have been told your liver numbers have not fully normalized despite real weight loss, this is a useful piece of context rather than a cause for alarm. It suggests that gap is a known, mechanistically real phenomenon and an active area of research, not a sign that something has gone wrong or that you are doing anything incorrectly. There is nothing to buy or take differently because of this study. The honest takeaway is narrower and more useful than that: weight and liver inflammation look like two separate dials, and future treatment may need to turn both.
Primary sources
Common questions
Is there a GDF15 drug or supplement I can take today?
No. This pathway was discovered in mouse models of advanced fatty liver disease, and there is no human GDF15 therapy available right now. High circulating GDF15 in humans is actually a known marker of illness and physical wasting, so more GDF15 is not automatically a good thing, and nothing about this study is a reason to try to raise it yourself.
Does losing weight on a GLP-1 drug not fix liver inflammation?
Liver inflammation often persists in real patients even after significant weight loss on current GLP-1 medications, which is exactly the gap this study speaks to. It suggests weight and liver inflammation may be two separate problems that need two separate levers, rather than one automatically following from the other, though this specific mechanism has only been shown in mice so far.
Should I be worried about the drug company involvement in this study?
It is worth knowing about. Novo Nordisk collaborated on the study, provided research support and supplied the GDF15 used, and the senior author co founded a company developing a liver disease drug candidate. That does not make the finding false, but per standard research practice it means the result should be treated as unproven until it is replicated by a group without those ties. Non commercial funders, including government science agencies, partly offset this.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.